The BLOC1S5 Knockout SK-HEP-1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population in which the BLOC1S5 gene has been disrupted to create a loss-of-function model. This knockout model enables the investigation of BLOC-1 complex function in lysosome-related organelle biogenesis and vesicular trafficking pathways. The polyclonal nature ensures representation of diverse CRISPR-mediated editing outcomes, providing a robust system for functional analyses without requiring clonal selection.
SK-HEP-1 is a human liver adenocarcinoma cell line originally isolated from the ascites of a patient with hepatic cancer. These epithelial cells display both mesenchymal and epithelial characteristics, making them a valuable model for studying hepatocellular carcinoma biology. Their dual phenotype facilitates the examination of endosomal trafficking and organelle dynamics in the context of hepatic tumorigenesis, where lysosomal dysfunction contributes to cancer progression and therapeutic resistance.
BLOC1S5 encodes a core subunit of the BLOC-1 complex, which coordinates cargo sorting from early endosomes to lysosome-related organelles such as melanosomes and platelet dense granules. BLOC1S5 interacts with BLOC-1 components including BLOC1S1, BLOC1S2, BLOC1S3, DTNBP1, SNAPIN, PLDN, CNO, and KXD1, and operates downstream of transcription factors MITF and SOX10. Together with the AP-3 complex, BLOC-1 mediates the transport of key proteins like TYRP1 and ATP7A. Disruption of BLOC1S5 impairs BLOC-1 function, resulting in defective membrane protein delivery and organelle biogenesis.
In SK-HEP-1 cells, BLOC1S5 knockout provides a clinically relevant platform to explore the intersection of endolysosomal trafficking and liver cancer cell physiology. Lysosomal pathway alterations are known to influence autophagy, metabolic adaptation, and drug sensitivity in hepatocarcinoma. This model therefore allows researchers to examine how BLOC-1-dependent trafficking defects affect lysosomal enzyme activity, autophagy flux, and responses to chemotherapeutics, while also serving as a tool to study Hermansky-Pudlak syndrome and platelet dense granule deficiency in a hepatic context.
Typical applications include investigations of lysosome-related organelle biogenesis defects, modeling of Hermansky-Pudlak syndrome, and characterization of protein trafficking in liver cancer. Researchers can perform Western blotting for BLOC1S5 knockout validation, immunofluorescence for LAMP1/LAMP2 to assess lysosomal morphology, lysosomal enzyme activity assays, autophagy flux analysis, transferrin receptor recycling assays, electron microscopy, proliferation assays, and drug sensitivity profiling. The polyclonal knockout population is ideal for functional genomics screens and mechanistic studies of vesicle-mediated transport. For further information, please contact Ascent Research.
